Huang J et al (2022) Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers (Basel). https://doi.org/10.3390/cancers14092230

Article  PubMed  PubMed Central  Google Scholar 

Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen R (Jan 2018) No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands, (in eng). Eur J Cancer 88:31–37. https://doi.org/10.1016/j.ejca.2017.10.030

Pignata S, S CC, Du Bois A, Harter P, Heitz F (2017) Treatment of recurrent ovarian cancer, (in eng), Ann Oncol, vol. 28, no. suppl_8, pp. viii51-viii56, Nov 1 https://doi.org/10.1093/annonc/mdx441

Ozols RF et al (2023) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 41(25):4077–4083. https://doi.org/10.1200/jco.22.02766

Article  PubMed  Google Scholar 

Orr B, Edwards RP (2018) Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am 32(6):943–964. https://doi.org/10.1016/j.hoc.2018.07.010

Article  PubMed  Google Scholar 

de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O (2017) Pharmacological principles of intraperitoneal and bidirectional chemotherapy, (in eng), Pleura Peritoneum, vol. 2, no. 2, pp. 47–62, Jun 1 https://doi.org/10.1515/pp-2017-0010

Jacquet P, Sugarbaker PH (1996) Peritoneal-plasma barrier, (in eng), Cancer Treat Res, vol. 82, pp. 53–63. https://doi.org/10.1007/978-1-4613-1247-5_4

Sugarbaker PH, Stuart OA, Vidal-Jove J, Pessagno AM, DeBruijn EA (1996) Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration, (in eng). Cancer Treat Res 82:41–52. https://doi.org/10.1007/978-1-4613-1247-5_3

Article  CAS  PubMed  Google Scholar 

Cascales-Campos P, Gil J, Feliciangeli E, Parrilla P (2015) Hipec in ovarian cancer: treatment of a new era or is it the end of the pipeline? Gynecol Oncol 139(2):363–368. https://doi.org/10.1016/j.ygyno.2015.06.012

Article  CAS  PubMed  Google Scholar 

Zivanovic O et al HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer, (in eng). Int J Cancer, 136, 3, pp. 699–708, Feb 1 2015, https://doi.org/10.1002/ijc.29011

Aronson SL et al (2023) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol 24(10):1109–1118. https://doi.org/10.1016/s1470-2045(23)00396-0

Article  CAS  PubMed  Google Scholar 

Lim MC et al (2022) Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer. JAMA Surg 157(5):374–383. https://doi.org/10.1001/jamasurg.2022.0143

Article  PubMed  PubMed Central  Google Scholar 

Lee JY et al (2023) Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with advanced-stage ovarian cancer who had received neoadjuvant chemotherapy. JAMA Surg 158(11):1133–1140. https://doi.org/10.1001/jamasurg.2023.3944

Article  PubMed  PubMed Central  Google Scholar 

Bhatt A et al (2021) Hipec methodology and regimens: the need for an expert consensus. Ann Surg Oncol 28(13):9098–9113. https://doi.org/10.1245/s10434-021-10193-w

Article  PubMed  Google Scholar 

Kireeva G et al (2020) Modeling of chemoperfusion vs. intravenous administration of Cisplatin in Wistar rats: adsorption and tissue distribution. Molecules 25(20):4733

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cashin PH, Ehrsson H, Wallin I, Nygren P, Mahteme H (2013) Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis, (in eng), Eur J Clin Pharmacol, vol. 69, no. 3, pp. 533 – 40, Mar https://doi.org/10.1007/s00228-012-1405-4

Kim YJ, Lee HM, Lee GE, Yoo JH, Lee HJ, Rhie SJ (2024) Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis, Pharmaceuticals, vol. 17, no. 8, p. 1095, [Online]. Available: https://www.mdpi.com/1424-8247/17/8/1095

Chakrabarti S, Michor F (2017) Pharmacokinetics and drug interactions determine optimum combination strategies in computational models of cancer evolution. Cancer Res 77(14):3908–3921. https://doi.org/10.1158/0008-5472.Can-16-2871

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harlev C et al (2025) Dynamic assessment of local abdominal tissue concentrations of Cisplatin during a HIPEC procedure: insights from a porcine model. Ann Surg Oncol. https://doi.org/10.1245/s10434-025-17000-w

Harlev C, Intraperitoneal Chemotherapy On Abdominal Tissue Concentrations Of Cisplatin (2025) The Role Of Hyperthermia In : Insights From A Porcine Model, International Journal of Gynecological Cancer, vol. 35, no. 2. https://doi.org/10.1016/j.ijgc.2024.100123

Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8(6):e1000412. https://doi.org/10.1371/journal.pbio.1000412

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hammarlund-Udenaes M (2017) Microdialysis as an important technique in systems pharmacology-a historical and methodological review. AAPS J 19(5):1294–1303. https://doi.org/10.1208/s12248-017-0108-2

Article  CAS  PubMed  Google Scholar 

Schmedes AV et al (Feb 3 2024) Analysis of free cisplatin in microdialysates and plasma ultrafiltrate by liquid chromatography-tandem mass spectrometry, (in eng). J Chromatogr B Analyt Technol Biomed Life Sci 1235:124040. https://doi.org/10.1016/j.jchromb.2024.124040

Zhang T et al (2024) Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy, (in eng), Cancer Chemother Pharmacol, vol. 95, no. 1, p. 13, Dec 26 https://doi.org/10.1007/s00280-024-04727-8

Tannock IF, Lee CM, Tunggal JK, Cowan DSM, Egorin MJ (2002) Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to Chemotherapy1. Clin Cancer Res 8(3):878–884

CAS  PubMed  Google Scholar 

Toutain PL, Ferran A, Bousquet-Mélou A (2010) Species differences in pharmacokinetics and pharmacodynamics, (in eng), Handb Exp Pharmacol, no. 199, pp. 19–48. https://doi.org/10.1007/978-3-642-10324-7_2